Nermin Graise, MD
Ophthalmology · Warwick, RINPI 1770879298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,925 of the $60,264 with a category attached, or 81.2%. Bausch & Lomb Americas Inc. accounts for 94.6% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $25,708, more than ten times the $377 reported in 2019. Among ophthalmology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $249.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$57K
- Sun Pharmaceutical Industries Inc.$595
- AbbVie$512
- Glaukos Corporation$423
- Ocular Therapeutix, Inc.$364
- Sight Sciences, Inc.$208
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$48,92581%
- Travel & lodging$4,9828%
- Food & beverage$6,30810%
- Education$300%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 107 | $56,989 |
| Sun Pharmaceutical Industries Inc. | 29 | $595 |
| AbbVie(2 entities) | 28 | $512 |
| Glaukos Corporation | 6 | $423 |
| Ocular Therapeutix, Inc. | 14 | $364 |
| Sight Sciences, Inc. | 3 | $208 |
| Kala Pharmaceuticals, Inc. | 11 | $192 |
| Rayner Intraocular Lenses Limited | 10 | $190 |
| Novartis | 4 | $164 |
| Alcon | 6 | $147 |
| Oyster Point Pharma, Inc. | 5 | $101 |
| Tarsus Pharmaceuticals, Inc. | 5 | $89 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $83 |
| Dompe US, Inc. | 3 | $78 |
| Biotissue Holdings Inc. | 3 | $53 |
| Beaver-visitec International, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Omeros Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,264 in reported general payments places this provider in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 209 | $166,629 |
| XiidraLifitegrast | 31 | $37,802 |
| LumiganBimatoprost | 88 | $27,284 |
| Prednisolone Acetate | 837 | $25,682 |
| MieboPerfluorohexyloctane/Pf | 29 | $22,031 |
| ProlensaBromfenac Sodium | 46 | $15,702 |
| Ketorolac Tromethamine | 808 | $14,842 |
| CequaCyclosporine | 19 | $11,960 |
| Ofloxacin | 903 | $10,481 |
| Cyclosporine | 27 | $8,416 |
| Bromfenac Sodium | 40 | $8,167 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $6,535 |
| Lotemax SmLoteprednol Etabonate | 23 | $5,764 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $4,696 |
| Latanoprost | 342 | $4,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $512 | $198,609316 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $56,989 | $59,83360 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $83 | $21,46769 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $595 | $11,96019 claims |
| AlconSimbrinza | $147 | $6,53529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Warwick
- Leah KammerdienerWarwick$6K
- Vikrant DonthamsettiWarwick$4K
- Richard SayeghWarwick$4K
- Glenn PrescodWarwick$4K
- Michael O'BrienWarwick$1K
- Richard LuckWarwick$1K
- Tatyana SerednyakovaWarwick$968
- Thomas LeddyWarwick$338
- Moya BrooksWarwick$285
- Paul KochWarwick$196
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.